Clinical trials: Chimeric Antigen Receptor T-cell Therapy
Immune Thrombocytopenia (ITP)
Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Primary Objective: To evaluate the safety and efficacy of CHT105 Injection in subjects with relapsed/refractory autoimmune diseases.
- Trial name
- NCT07811622
- Testing
- CHT105
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Nanjing Miracle Biotechnology Co., Ltd.
CRC, Solid Tumor
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of advanced NKG2DL+ solid tumors.
- Trial name
- NCT05382377
- Testing
- KD-025
- Where
- China
- Volunteers
- 18 people
- Sponsor
- jianming xu
Leukemia, B-Cell
Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
This is a gene transfer study for patients with a type of blood cancer called Acute Lymphoblastic Leukemia (ALL) that has come back or has not gone away after treatment.
- Trial name
- TRICAR-ALL (NCT05010564)
- Testing
- Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Baylor College of Medicine
Leukemia
Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation
Efficacy study about donor derived CD19-target T cell to treat B-ALL post hematopoietic stem cell transplantation
- Trial name
- NCT04336501
- Testing
- IM19 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Scleroderma, Autoimmune Diseases
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
- Trial name
- NCT05085444
- Testing
- Assigned Interventions CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Zhejiang University
Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Background: Chemokine receptor 4 (CCR4) is a protein that is found on the surface of certain T-cell lymphoma cells and is common in mature T-cell cancers.
- Conditions
- Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT07055477
- Testing
- Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- NCT07825389
- Testing
- C-CAR168
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- AbelZeta Inc.
Acute Lymphoblastic Leukemia
CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia
This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous chimeric antigen receptor (CAR) T cells targeting both CD19 and CD22, manufactured with T-Charge(TM) process.
- Trial name
- NCT05168748
- Testing
- IMJ995 single agent
- Sponsor
- Novartis Pharmaceuticals
Adult B Acute Lymphoblastic Leukemia
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
This is an open, single-arm, phase I/phase II clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Relapsed Refractory (R/R) adult acute lymphoblastic…
- Trial name
- NCT04626726
- Testing
- CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Hematologic Malignancies, Solid Tumors
Follow-Up for Study Participants Treated With an Allogeneic CAR T Cell Product
An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study.
- Trial name
- NCT06925685
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Allogene Therapeutics
Acute Myeloid Leukemia
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
This is a single-center, open-label, non-randomized, single-arm Phase 1 Study to evaluate safety and tolerability of optimized Dual CD33/CLL1 CAR T Cells in subjects with refractory or relapsed acute myeloid leukemia.
- Trial name
- NCT05248685
- Testing
- Dual CD33/CLL1 CAR T
- Where
- China
- Sponsor
- Beijing Boren Hospital
Multiple Myeloma, Relapsed/Refractory
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
To evaluate the safety and tolerability of chimeric antigen receptor gene-modified T cells targeting BCMA for the treatment of relapsed/refractory multiple myeloma
- Trial name
- NCT06581640
- Testing
- CAR-T treatment
- Where
- China
- Volunteers
- 5 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Neuroblastoma
3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
Subjects that have relapsed or refractory neuroblastoma are invited to take part in this gene transfer research study. We have found from previous research that we can put a new gene called a chimeric antigen receptor (CAR) into…
- Trial name
- GRAIN (NCT01822652)
- Testing
- iC9-GD2 T Cells - frozen, iC9-GD2 T Cells - fresh, Cytoxan
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Baylor College of Medicine
AML, Refractory/Relapse Acute Myeloid Leukemia
Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML
A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
- Trial name
- NCT07617285
- Testing
- CAR-T cells chimeric antigen receptor T cells
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Peking University People's Hospital
Multiple Myeloma, Multiple Myeloma in Relapse
Universal CAR-T Cell Therapy for MM
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Trial name
- NCT07248176
- Testing
- Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Bioray Laboratories
Multiple Myeloma
Study of BCMA CAR-T in Multiple Myeloma
The purpose of this study is to infusion BCMA CAR-T cells to the patients with relapsed and refractory multiple myeloma(MM), to assess the safety and feasibility of this strategy.
- Trial name
- NCT03322735
- Testing
- Fludarabine, Cyclophosphamide, BCMA CAR-T
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Henan Cancer Hospital
T-cell Acute Lymphoblastic Leukemia
CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia
This is a phase I, interventional, single arm, open label, clinical study to evaluate the safety and tolerability of CD5 CAR-T cells in refractory/relapsed CD5+ T-ALL patients who have no available curative treatment options.
- Trial name
- NCT05596266
- Testing
- CD5 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuanwu Hospital, Beijing
Solid Tumor, Adult, Advanced Cancer
PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies
This is a single-arm, open-label, one center, dose escalation clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibody and chimeric antigen receptor…
- Trial name
- NCT03030001
- Testing
- PD-1 antibody expressing mesothelin specific CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ningbo Cancer Hospital
Nectin4-positive Advanced Malignant Solid Tumor
Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors
According to the high expression of tumor cell-associated antigen Nectin4 in patients with solid tumors such as non-small cell lung cancer, breast cancer, ovarian cancer, bladder cancer, and pancreatic cancer, and in order to…
- Trial name
- NCT03932565
- Testing
- CAR-T therapy for nectin4-positive malignant solid tumor
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Sixth Affiliated Hospital of Wenzhou Medical University
T Cell Lymphoblastic Lymphoma
Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL
This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of T cells expressing CD7 chimeric antigen receptors (referred to as "BT-007 CAR-T cells") in patients with relapsed or refractory…
- Trial name
- NCT05554575
- Testing
- BT-007 CD7 CAR-T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Bioceltech Therapeutics, Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.